Is Egrifta (Tesamorelin) Legal in Louisiana? How to Access It Legally
HealthRX.com
Egrifta is FDA-approved, but Louisiana rules are not covered here
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy only [2]
- Current products / Egrifta SV 2 mg vial (1.4 mg daily) and Egrifta WR 11.6 mg vial (1.28 mg daily) [2][3]
- Route / Once-daily subcutaneous injection into the abdomen [2][3]
- Compounding / No FDA category-based statement; not among the six peptides in the HHS draft policy [4][5][6][7][8]
- Sport / Named on WADA's Prohibited List, prohibited at all times [9][10]
What is Egrifta's federal status?
FDA lists Egrifta (tesamorelin acetate) as a prescription product under application BLA 022505, originally approved November 10, 2010 [1]. The current labels are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial; both are dated July 29, 2026, and both are given as once-daily subcutaneous injections [2][3]. Tesamorelin is a peptide, a synthetic analog of human growth hormone-releasing factor, not growth hormone itself [2].
Questions worth asking
What the approval covers
There is one approved use: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2]. The label states that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue, and that it is not indicated for weight loss management because its effect on weight is neutral [2]. The label also states there are no data to support improved compliance with antiretroviral therapy [2].
The labels contraindicate tesamorelin in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), and known hypersensitivity to tesamorelin or its excipients [2][3].
Can tesamorelin be compounded?
FDA has made no category-based statement about compounding tesamorelin. It does not appear on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) [4], it is in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) [5] or its list for outsourcing facilities (updated March 21, 2025) [6], and it is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding filed October 28, 2026: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [7][8].
Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].
Doses and monitoring on the labels
Egrifta SV is labeled as 1.4 mg (0.35 mL of the reconstituted solution) once daily, while Egrifta WR is labeled as 1.28 mg (0.16 mL) once daily, both injected into the abdomen. The labels say the two products differ in dose, vial number, reconstitution and storage, and are not substitutable [2][3].
The label says to monitor IGF-1 during therapy and to evaluate glucose before and during treatment [2]. In the trials, among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated 52 weeks, 34% and 23% [2]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26 (hazard ratio about 3.3, 95% CI 1.4 to 9.6) [2].
Sport: WADA prohibits it
WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone-releasing factors and their analogues, prohibited at all times, in and out of competition [9]. It is on the 2026 List, in force since January 1, 2026, and stays on the 2027 List [9][10].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is Egrifta legal in Louisiana?
Can a pharmacy compound tesamorelin?
What dose does the label recommend?
Is tesamorelin approved for weight loss?
Is tesamorelin allowed in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Has Tesamorelin been approved by the FDA?
Yes. FDA lists Egrifta (tesamorelin acetate) as a prescription product under application BLA 022505, originally approved November 10, 2010. Its one approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Was Egrifta discontinued?
No discontinuation is reported. FDA lists Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial) as current products, with both labels dated July 29, 2026, and both given as once-daily subcutaneous injections.
Which peptides are now legal?
No general list of legal peptides is given. Six peptides are named in HHS's draft enforcement-discretion policy for compounding: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of them.
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.